Dementia with Lewy Bodies (DLB)

1. Topic Overview (Clinical Overview)

Summary

Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer's disease, accounting for 10-15% of all dementia cases at autopsy. [1,2] It is characterised by intracytoplasmic alpha-synuclein protein aggregates (Lewy bodies and Lewy neurites) distributed throughout the cortex, limbic system, and brainstem. [3] The cardinal clinical syndrome comprises a triad of fluctuating cognition with pronounced variations in attention and alertness, recurrent complex visual hallucinations, and spontaneous parkinsonism. [4] A fourth core feature, REM sleep behaviour disorder (RBD), was added to diagnostic criteria in 2017 and may precede cognitive decline by more than a decade, representing a prodromal phase of synucleinopathy. [5,6]

DLB demonstrates profound cholinergic deficits exceeding those seen in Alzheimer's disease, which explains both the prominence of visual hallucinations and the robust response to cholinesterase inhibitors. [7] A critical management consideration is severe neuroleptic sensitivity—up to 50% of DLB patients develop potentially fatal reactions to dopamine-blocking antipsychotics, with manifestations including severe rigidity, altered consciousness, autonomic instability, and rhabdomyolysis (neuroleptic malignant-like syndrome). [8,9] Typical antipsychotics (haloperidol, risperidone) are absolutely contraindicated.

The "one-year rule" differentiates DLB from Parkinson's disease dementia (PDD): if dementia develops before or within one year of motor parkinsonism, the diagnosis is DLB; if dementia emerges more than one year after established parkinsonism, it is classified as PDD. [10] This arbitrary temporal distinction separates two conditions with identical pathological substrate—widespread cortical and brainstem Lewy body deposition.

Key Facts

• Epidemiology: 10-15% of all dementia cases; 20-25% when combined with Alzheimer pathology. [1,2]
• Pathology: Cortical and brainstem alpha-synuclein aggregates (Lewy bodies and Lewy neurites). [3]
• Core Features (2017 Criteria): (1) Fluctuating cognition, (2) Visual hallucinations, (3) REM sleep behaviour disorder, (4) Spontaneous parkinsonism. [4]
• Molecular Mechanism: Alpha-synuclein misfolding and aggregation; profound cholinergic deficit. [7,11]
• Indicative Biomarkers: Reduced striatal dopamine transporter uptake on FP-CIT SPECT (DaTscan); decreased cardiac MIBG uptake; polysomnographic confirmation of REM without atonia. [4,12]
• Treatment: Rivastigmine (licensed for DLB) and donepezil improve cognition, hallucinations, and neuropsychiatric symptoms. [13,14]
• Critical Safety Issue: Severe neuroleptic sensitivity in ~50% of patients—avoid all typical and most atypical antipsychotics. [8,9]
• Prognosis: More rapid cognitive decline than Alzheimer's disease; median survival 5-7 years from diagnosis. [15]

Clinical Pearls

"Fluctuating Cognition": Alertness and cognitive performance vary dramatically over hours to days. Patients may be lucid and conversant in the morning, profoundly confused by afternoon. This fluctuation is not delirium—it is an intrinsic feature of DLB and reflects dysfunctional cortical cholinergic and noradrenergic modulation.

"Visual Hallucinations Before Memory Loss": Complex, well-formed visual hallucinations (people, children, animals) appear early in DLB, often before significant memory impairment. This contrasts with Alzheimer's disease, where hallucinations are late features. Patients typically retain partial insight initially.

"Antipsychotics Can Kill": Neuroleptic sensitivity reactions occur in up to 50% of DLB patients, with mortality rates of 13-30% when typical antipsychotics are used. [9] AVOID haloperidol, risperidone, olanzapine. If absolutely necessary for severe psychosis, use quetiapine (12.5-50mg) or clozapine with extreme caution and close monitoring.

"RBD as a Prodromal Marker": REM sleep behaviour disorder (acting out dreams—punching, kicking, vocalising during REM sleep) can precede cognitive symptoms by 10-15 years. Longitudinal studies show 80-90% of patients with idiopathic RBD develop a synucleinopathy (DLB, Parkinson's, or MSA) within 10-14 years. [5,6]

"The One-Year Rule": Dementia within 1 year of parkinsonism = DLB. Dementia > 1 year after parkinsonism = PDD. This is an arbitrary clinical distinction—the pathology is identical. The rule exists for research consistency, not biological validity.

"Cholinesterase Inhibitors Work Better in DLB": The cortical cholinergic deficit in DLB is more severe than in Alzheimer's disease, making cholinesterase inhibitors (rivastigmine, donepezil) particularly effective for cognitive symptoms, hallucinations, and apathy. [7,14]

Why This Matters Clinically

DLB is frequently misdiagnosed as Alzheimer's disease, Parkinson's disease, or delirium, leading to inappropriate management. Recognising DLB prevents catastrophic iatrogenic harm from antipsychotics, guides appropriate pharmacotherapy (cholinesterase inhibitors), and informs prognostic counselling. Early identification of prodromal RBD offers opportunities for future disease-modifying interventions.

---

2. Epidemiology

Prevalence and Incidence

Geographic and Ethnic Variation

• DLB prevalence appears consistent across populations worldwide. [2]
• Some studies suggest lower recognition rates in Asian populations due to phenotypic variation and diagnostic criteria application. [17]

Lewy Body Spectrum Disorders

DLB exists within a continuum of alpha-synucleinopathies:

All share alpha-synuclein aggregation but differ in anatomical distribution and cellular involvement. [3,10]

Coexistent Pathology

• Pure DLB is uncommon at autopsy. [2]
• 60-90% of DLB cases have concurrent Alzheimer pathology (amyloid plaques, tau tangles), typically less severe than in pure Alzheimer's disease. [18]
• Coexistent vascular pathology in ~30%. [2]

---

3. Pathophysiology

Molecular Pathology: Alpha-Synuclein Aggregation

Alpha-Synuclein

Lewy Bodies and Lewy Neurites

Pathological Staging (Braak Staging for Lewy Pathology): [20]

1. Stage 1-2: Medulla/olfactory bulb.
2. Stage 3-4: Substantia nigra, midbrain.
3. Stage 5-6: Cortical (limbic → neocortex).

DLB typically presents at Stages 5-6 (diffuse cortical involvement), whereas Parkinson's disease is diagnosed at Stages 3-4 (brainstem predominant).

Neurochemical Deficits

Cholinergic Deficit

• Severe loss of cholinergic neurons in nucleus basalis of Meynert (basal forebrain). [7]
• Cholinergic deficit exceeds Alzheimer's disease (explains robust response to cholinesterase inhibitors). [7]
• Contributes to fluctuating attention, hallucinations, and cognitive impairment.

Dopaminergic Deficit

• Degeneration of substantia nigra pars compacta → reduced striatal dopamine. [3]
• Underlies parkinsonism and positive DaTscan findings (reduced dopamine transporter binding). [12]

Other Neurotransmitter Systems

• Noradrenergic: Locus coeruleus degeneration → noradrenergic deficit → contributes to fluctuations, autonomic dysfunction. [21]
• Serotonergic: Raphe nucleus involvement → possible role in depression, hallucinations. [21]

Mechanisms of Core Clinical Features

Genetic and Environmental Factors

Genetic Risk

• Sporadic in > 95% of cases. [19]
• SNCA gene (alpha-synuclein): Rare duplications/triplications cause autosomal dominant disease; point mutations rare in DLB. [19]
• GBA mutations (glucocerebrosidase): Most common genetic risk factor for DLB/Parkinson's. Heterozygous carriers have 5-10x increased risk. [25] GBA mutations associated with earlier onset, more rapid progression.
• APOE ε4 allele: Associated with coexistent Alzheimer pathology and more rapid cognitive decline in DLB. [18]

Environmental/Lifestyle

• No established environmental causes.
• Possible protective factors: Caffeine, physical activity (weak evidence).

---

4. Clinical Features

Core Clinical Features (2017 McKeith Consensus Criteria) [4]

1. Fluctuating Cognition

Definition: Spontaneous, unpredictable variations in cognition, attention, and alertness.

Assessment:

• Clinician Assessment of Fluctuations (CAF) scale. [26]
• Mayo Fluctuations Scale. [26]
• Caregiver interview essential—fluctuations often not evident during brief consultation.

2. Recurrent Visual Hallucinations

Definition: Recurrent, complex, well-formed visual hallucinations.

Assessment:

• Neuropsychiatric Inventory (NPI) hallucination subscale. [27]
• Direct questioning: "Have you seen things that other people can't see?"

3. REM Sleep Behaviour Disorder (RBD)

Definition: Dream-enactment behaviour during REM sleep due to loss of REM muscle atonia.

Gold Standard Diagnosis: Polysomnography demonstrating REM sleep without atonia. [4]

Screening Question: "Have you or your partner noticed that you act out your dreams (punching, kicking, shouting) during sleep?"

4. Spontaneous Parkinsonism

Definition: Extrapyramidal motor features arising spontaneously (not drug-induced).

Characteristics of DLB Parkinsonism vs. Parkinson's Disease: [10]

---

Supportive Clinical Features [4]

---

Cognitive Profile

Key Point: DLB is a "cortical-subcortical" dementia with prominent frontal-executive and posterior cortical (visuospatial) dysfunction, contrasting with the medial temporal/hippocampal memory-dominant profile of Alzheimer's disease.

---

Autonomic Dysfunction

Clinical Significance: Autonomic features contribute to falls, syncope, and reduced quality of life. Neurogenic orthostatic hypotension can be severe.

---

5. Diagnosis

Diagnostic Criteria: 2017 McKeith Consensus [4]

Essential Feature

Progressive cognitive decline of sufficient severity to interfere with normal social or occupational function.

Core Clinical Features (4)

1. Fluctuating cognition with pronounced variations in attention and alertness.
2. Recurrent visual hallucinations (well-formed, detailed).
3. REM sleep behaviour disorder (precede or follow cognitive decline).
4. One or more spontaneous cardinal features of parkinsonism (bradykinesia, rest tremor, rigidity). Must occur > 1 year after cognitive decline onset (otherwise consider PDD).

Indicative Biomarkers (3)

1. Reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET (FP-CIT SPECT/"DaTscan"; ¹²³I-FP-CIT, ¹⁸F-DOPA PET). [12]
2. Low uptake ¹²³I-MIBG myocardial scintigraphy. [4,12]
3. Polysomnographic confirmation of REM sleep without atonia. [4]

Supportive Biomarkers

• Relative preservation of medial temporal lobe structures on CT/MRI (vs. atrophy in Alzheimer's disease). [28]
• Generalised low uptake on SPECT/PET perfusion/metabolism scan with reduced occipital activity ± cingulate island sign (relatively preserved posterior cingulate metabolism compared to precuneus/cuneus). [29]
• Prominent posterior slow-wave activity on EEG with periodic fluctuations in the pre-alpha/theta range. [30]

Diagnostic Categories

DLB vs. Parkinson's Disease Dementia: The "One-Year Rule" [10]

Important Note: This distinction is arbitrary and for research/clinical classification purposes. The underlying pathology (diffuse Lewy body disease) is identical. Management principles are the same.

---

Investigations

Cognitive Assessment

Structural Neuroimaging

Functional Neuroimaging / Molecular Imaging

Polysomnography

CSF Biomarkers

Note: CSF biomarkers have limited utility for DLB diagnosis (overlap with AD). Used mainly in research or to assess for concurrent AD pathology.

EEG

Clinical Utility: EEG abnormalities are common but not specific. Supportive biomarker, not diagnostic.

Routine Blood Tests

Purpose: Exclude reversible causes of cognitive impairment ("dementia mimics").

Autonomic Function Tests (if indicated)

Indications: Severe orthostatic hypotension, unexplained syncope, severe autonomic symptoms.

---

Summary: Diagnostic Pathway

Step 1: Clinical Assessment
• Detailed history (patient + informant)
• Cognitive testing (MoCA, ACE-III, clock drawing)
• Assess core features: fluctuations, hallucinations, RBD, parkinsonism
• Neurological examination

Step 2: Investigations
• MRI brain (exclude other causes; assess medial temporal lobes)
• Routine bloods (exclude reversible causes)
• ± DaTscan (if diagnostic uncertainty; differentiates DLB from AD)
• ± Polysomnography (if RBD suspected but unclear from history)
• ± EEG (if diagnostic uncertainty; supportive)

Step 3: Diagnosis
• Apply 2017 McKeith Criteria
• Probable DLB: 2+ core features OR 1 core + 1 indicative biomarker
• Possible DLB: 1 core feature OR 1 indicative biomarker

Step 4: Exclude Differentials
• Alzheimer's disease (memory-dominant, normal DaTscan)
• Vascular dementia (MRI infarcts, stepwise decline)
• Parkinson's disease dementia (dementia > 1 year after parkinsonism)
• Delirium (acute, identifiable trigger, reversible)

---

6. Management

Principles of Management

1. Multidisciplinary Team Approach: Neurology/geriatrics, psychiatry, nursing, occupational therapy, physiotherapy, speech therapy, social services, palliative care.
2. Pharmacological:
   • Cholinesterase inhibitors for cognition and neuropsychiatric symptoms (first-line).
   • Avoid typical antipsychotics (severe neuroleptic sensitivity).
   • Cautious use of levodopa for parkinsonism (limited efficacy; may worsen hallucinations).
   • Treat RBD (clonazepam, melatonin).
   • Manage autonomic dysfunction.
3. Non-Pharmacological: Environmental modifications, carer education and support, safety interventions, falls prevention.
4. Safety: Address falls risk, driving, capacity assessment.
5. Advance Care Planning: Early discussions about wishes, advance directives, DNAR.

---

Pharmacological Management

Cognition and Neuropsychiatric Symptoms: Cholinesterase Inhibitors (FIRST-LINE)

Efficacy in DLB:

• More effective than in Alzheimer's disease (greater cholinergic deficit in DLB). [7,14]
• Improve cognition (attention, executive function, global cognition).
• Reduce hallucinations, delusions, apathy, anxiety.
• May improve fluctuations in some patients.
• Continue long-term (benefits sustained; rapid decline on withdrawal).

Adverse Effects:

• Gastrointestinal: Nausea, vomiting, diarrhoea, anorexia, weight loss (most common; dose-related; transient).
• Cardiovascular: Bradycardia, heart block (rare; caution in cardiac conduction disease).
• Cholinergic: Increased secretions, urinary urgency, muscle cramps.
• Sleep: Insomnia, nightmares (give morning dose if problematic).

Contraindications: Sick sinus syndrome, significant heart block (unless pacemaker).

Visual Hallucinations and Psychosis

First-Line: Cholinesterase inhibitors (rivastigmine, donepezil)—often sufficient. [13,14]

If Severe, Distressing, and Not Responsive to Cholinesterase Inhibitors:

Critical Safety Message:

"ANTIPSYCHOTICS ARE DANGEROUS IN DLB." Neuroleptic sensitivity reactions occur in ~50% of patients, with mortality rates of 13-30%. [8,9] Avoid unless psychosis is severe, distressing, and unresponsive to non-pharmacological measures and cholinesterase inhibitors. If essential, use quetiapine or clozapine at lowest effective dose with close monitoring. Never use haloperidol, risperidone, or olanzapine.

Parkinsonism

Management Dilemma: Hallucinations vs. Parkinsonism:

• Levodopa may improve motor symptoms but worsen hallucinations.
• Antipsychotics may reduce hallucinations but worsen parkinsonism (and cause severe neuroleptic reactions).
• Cholinesterase inhibitors can help both (mild motor benefit + reduce hallucinations). [13,14]
• Pragmatic approach: Treat most disabling symptom; accept trade-offs; use non-pharmacological strategies.

REM Sleep Behaviour Disorder

Non-Pharmacological:

• Bedroom safety: Remove sharp objects, pad bed corners/floor, lower bed, separate beds if partner at risk.
• Avoid triggers: Alcohol, sleep deprivation, certain medications (SSRIs, TCAs can worsen RBD).

Depression and Anxiety

Non-Pharmacological: Psychological support, carer support, activity scheduling, social engagement.

Orthostatic Hypotension and Autonomic Dysfunction

Goal: Reduce symptomatic hypotension (dizziness, falls, syncope), not normalise BP. Accept lower BP if asymptomatic.

---

Non-Pharmacological Management

---

Safety and Falls Prevention

---

Advance Care Planning

• Early discussions about prognosis, disease trajectory, patient wishes.
• Advance Directive / Living Will: Document wishes about resuscitation, artificial nutrition/hydration, hospital admission.
• DNAR (Do Not Attempt Resuscitation) discussions if appropriate.
• Lasting Power of Attorney (UK) / Healthcare Proxy: Appoint decision-maker for when capacity lost.
• Anticipatory prescribing (end-of-life): Medications for pain, secretions, agitation, dyspnoea.

---

Palliative and End-of-Life Care

• Palliative care involvement when entering advanced stage (bedbound, minimally verbal, recurrent infections).
• Symptom control: Pain, secretions, dyspnoea, agitation.
• Avoid aggressive interventions (ICU, intubation, CPR) unless aligned with patient wishes.
• Family support: Bereavement support, understanding disease trajectory.

---

7. Complications

---

8. Prognosis and Outcomes

---

9. Differential Diagnosis

Alzheimer's Disease

Parkinson's Disease Dementia (PDD)

Clinical Point: DLB vs. PDD distinction is arbitrary ("one-year rule") and primarily for research classification. Pathology and management are the same.

Vascular Dementia (VaD)

Note: Mixed DLB + vascular pathology is common. Coexistent vascular disease may accelerate decline.

Delirium

Diagnostic Challenge: DLB fluctuations mimic delirium. Key: Delirium is acute and reversible; DLB fluctuations are chronic and progressive. However, DLB patients are highly susceptible to delirium (superimposed on baseline fluctuations). Always investigate for delirium triggers in DLB.

Frontotemporal Dementia (FTD)

Creutzfeldt-Jakob Disease (CJD)

---

10. Red Flags and When to Refer / Escalate

Red Flags (Urgent Action Required)

When to Refer

---

11. Patient and Carer Information

What is Dementia with Lewy Bodies?

Dementia with Lewy Bodies (DLB) is a type of dementia caused by abnormal deposits of a protein called alpha-synuclein in the brain. These deposits, called Lewy bodies, affect brain cells and cause problems with thinking, movement, sleep, and perception.

DLB is the second most common type of dementia after Alzheimer's disease, but it is often not recognised because its symptoms can vary and overlap with other conditions.

What Are the Main Symptoms?

How Is It Diagnosed?

There is no single test for DLB. Diagnosis is based on:

• Medical history and symptoms (from you and the patient).
• Cognitive tests (memory, thinking, drawing).
• Brain scans (MRI to rule out stroke or other problems; sometimes a DaTscan to look at brain chemicals—this can help confirm DLB).
• Blood tests to rule out other causes (thyroid problems, vitamin deficiencies).

How Is It Treated?

There is no cure for DLB, but treatments can help manage symptoms:

CRITICAL WARNING: AVOID CERTAIN MEDICATIONS

Some medications used to treat hallucinations or agitation (called "antipsychotics" or "neuroleptics") are VERY DANGEROUS in DLB. They can cause severe stiffness, confusion, high fever, and even death.

AVOID: Haloperidol, risperidone, olanzapine.

Always tell doctors, nurses, and paramedics that your loved one has Lewy Body Dementia and cannot have typical antipsychotic medications. Consider carrying a medical alert card or wearing a medical alert bracelet.

What Can I Expect?

• Progression: DLB tends to progress faster than Alzheimer's disease. Most people live 5-7 years after diagnosis, but this varies widely.
• Symptoms will change: Fluctuations, hallucinations, and movement problems may get worse over time. New problems (swallowing, infections, severe weakness) may appear.
• Falls are common: Movement problems, dizziness, and fluctuating attention increase fall risk. Home safety modifications are important.
• End of life: Most people with DLB eventually develop severe weakness, difficulty swallowing, and recurrent infections (especially chest infections). Palliative care can help manage symptoms and ensure comfort.

Tips for Carers

Support Organisations

• Lewy Body Society (UK): lewybody.org — Specialist charity for DLB. Information, support groups, helpline.
• Alzheimer's Society (UK): Provides support for all types of dementia, including DLB.
• Parkinson's UK: Also provides information on DLB (overlap with Parkinson's).
• Admiral Nurses (UK): Specialist dementia nurses who support families.

Key Messages

1. DLB is often misdiagnosed—if you suspect it, ask for a specialist opinion.
2. Medications can help—especially rivastigmine/donepezil.
3. AVOID dangerous antipsychotics—carry a medical alert card.
4. Hallucinations are part of the disease—they don't mean your loved one is "mad."
5. Carers need support—caring for someone with DLB is exhausting. Ask for help early.

---

12. Exam Scenarios and High-Yield Teaching Points

Scenario 1: Classic Presentation

Stem: A 76-year-old man is brought to the memory clinic by his wife. Over the past 18 months, he has developed progressive cognitive difficulties. His wife describes dramatic day-to-day variability—some days he is "almost normal," other days he is "completely lost." He has reported seeing "small children playing in the living room" on multiple occasions, although no children are present. On examination, he has a slow, shuffling gait, mild rigidity, and bradykinesia. MMSE is 21/30. Which investigation would be most helpful in confirming the diagnosis?

Answer: FP-CIT SPECT (DaTscan) showing reduced striatal dopamine transporter uptake. This patient has probable DLB (fluctuating cognition + visual hallucinations + parkinsonism = 3 core features). DaTscan is an indicative biomarker and would confirm presynaptic dopaminergic deficit, supporting DLB over Alzheimer's disease.

Teaching Point: DLB triad = fluctuations + hallucinations + parkinsonism. DaTscan differentiates DLB (abnormal) from Alzheimer's (normal).

---

Scenario 2: Neuroleptic Sensitivity

Stem: A 78-year-old woman with dementia is admitted from a care home with agitation and visual hallucinations. She is given 5mg haloperidol IM. Over the next 24 hours, she becomes increasingly rigid, confused, febrile (39.2°C), and tachycardic. What is the most likely diagnosis, and what is the immediate management?

Answer: Neuroleptic malignant-like syndrome (neuroleptic sensitivity reaction in DLB).
Immediate Management:

1. Stop haloperidol immediately.
2. Admit to hospital (may require HDU/ICU).
3. Supportive care: IV fluids, cooling, monitor vital signs.
4. Check CK, renal function (rhabdomyolysis risk).
5. Avoid further antipsychotics.
6. Consider dantrolene or bromocriptine if severe (limited evidence).

Teaching Point: Haloperidol is absolutely contraindicated in DLB. ~50% of DLB patients develop severe, potentially fatal reactions to typical antipsychotics. This is a red flag complication.

---

Scenario 3: One-Year Rule

Stem: A 72-year-old man was diagnosed with Parkinson's disease 5 years ago. He has been well-controlled on levodopa. Over the past year, he has developed memory problems, confusion, and visual hallucinations. What is the diagnosis?

Answer: Parkinson's Disease Dementia (PDD). Dementia developed > 1 year after established parkinsonism (diagnosed 5 years ago). If dementia had appeared within 1 year of parkinsonism onset, it would be DLB.

Teaching Point: The "one-year rule" is an arbitrary temporal distinction. Pathology (diffuse Lewy body disease) and management are identical for DLB and PDD.

---

Scenario 4: RBD as Prodromal Feature

Stem: A 68-year-old man presents to his GP with concerns from his wife that he "acts out his dreams." She describes him shouting, punching, and kicking during sleep, sometimes injuring her. He recalls vivid, action-filled dreams. He has no cognitive or motor symptoms. What is the diagnosis, and what is the prognosis?

Answer: REM Sleep Behaviour Disorder (RBD). This is idiopathic RBD (no cognitive/motor features yet).
Prognosis: 80-90% of patients with idiopathic RBD develop a synucleinopathy (DLB, Parkinson's disease, or MSA) within 10-14 years. [5,6] RBD is a prodromal marker of alpha-synuclein pathology.
Management: Treat RBD (clonazepam/melatonin), counsel about future risk, monitor for cognitive/motor symptoms.

Teaching Point: RBD precedes DLB by up to 10-15 years. It is a prodromal phase of synucleinopathy.

---

Scenario 5: Cholinesterase Inhibitor Efficacy

Stem: A 74-year-old woman is diagnosed with probable DLB (fluctuations, hallucinations, parkinsonism, reduced DaTscan uptake). She is started on rivastigmine. After 3 months, her family report significant improvement in her alertness, attention, and hallucinations. Why are cholinesterase inhibitors particularly effective in DLB?

Answer: DLB is characterised by a profound cholinergic deficit (loss of cholinergic neurons in nucleus basalis of Meynert), which is more severe than in Alzheimer's disease. [7] This cholinergic deficit underlies fluctuating attention and visual hallucinations. Cholinesterase inhibitors (rivastigmine, donepezil) work better in DLB than in Alzheimer's because of the greater cholinergic depletion.

Teaching Point: Cholinesterase inhibitors are first-line for DLB. Rivastigmine is licensed for DLB in the UK/Europe.

---

Scenario 6: Differential Diagnosis (DLB vs. Alzheimer's)

Stem: A 77-year-old woman presents with 2 years of progressive cognitive decline. She has prominent visuospatial difficulties (cannot copy a pentagon, gets lost in familiar places) and occasional visual hallucinations. Memory for recent events is relatively preserved when given cues. Examination reveals mild bradykinesia and rigidity. MRI brain shows minimal medial temporal lobe atrophy. FP-CIT SPECT shows reduced striatal uptake. What is the most likely diagnosis?

Answer: Dementia with Lewy Bodies (DLB).
Key Features:

• Visuospatial > memory impairment (contrast to Alzheimer's).
• Visual hallucinations (early feature in DLB, late in Alzheimer's).
• Parkinsonism (common in DLB, rare in Alzheimer's).
• Preserved medial temporal lobes on MRI (atrophied in Alzheimer's).
• Reduced DaTscan uptake (normal in Alzheimer's, abnormal in DLB).

Teaching Point: DLB has a posterior cortical/subcortical pattern (visuospatial, executive, parkinsonism) vs. Alzheimer's medial temporal pattern (memory). Imaging helps differentiate.

---

High-Yield Teaching Points

1. DLB Triad (Core Features): Fluctuating cognition + Visual hallucinations + Parkinsonism (+ RBD in 2017 criteria). [4]
2. Pathology: Cortical and brainstem alpha-synuclein aggregates (Lewy bodies). [3]
3. One-Year Rule: Dementia ≤1 year of parkinsonism = DLB. Dementia > 1 year after parkinsonism = PDD. [10]
4. Neuroleptic Sensitivity: ~50% of DLB patients have severe reactions to antipsychotics (rigidity, fever, death). AVOID haloperidol, risperidone. [8,9]
5. Cholinesterase Inhibitors: First-line. More effective in DLB than Alzheimer's (greater cholinergic deficit). Rivastigmine is licensed. [13,14]
6. DaTscan: Reduced striatal dopamine transporter uptake in DLB (indicative biomarker). Normal in Alzheimer's. [12]
7. RBD: Prodromal marker—can precede cognitive symptoms by 10-15 years. 80-90% develop synucleinopathy. [5,6]
8. Cognitive Profile: Executive/visuospatial > memory (vs. Alzheimer's: memory >> executive/visuospatial).
9. Levodopa: Limited efficacy in DLB (30-50% respond vs. 70-80% in Parkinson's). May worsen hallucinations. [10]
10. Prognosis: Median survival 5-7 years. Faster decline than Alzheimer's. [15]

---

13. Evidence Base and Guidelines

Key Guidelines

Landmark Studies

Rivastigmine in DLB (McKeith et al., 2000) [13]

• Design: Multicentre, randomised, double-blind, placebo-controlled trial.
• Population: 120 patients with probable DLB.
• Intervention: Rivastigmine (up to 12mg/day) vs. placebo for 20 weeks.
• Results:
  • Significant improvement in cognition (ADAS-cog), neuropsychiatric symptoms (NPI—hallucinations, delusions, apathy, anxiety), and activities of daily living.
  • NNT ~6 for clinically meaningful improvement.
  • Well-tolerated (nausea, vomiting in 25%, usually transient).
• Conclusion: Rivastigmine is effective for cognitive and neuropsychiatric symptoms in DLB. Led to licensing approval (Europe, UK).

Donepezil in DLB (Mori et al., 2012) [14]

• Design: Multicentre, randomised, double-blind, placebo-controlled trial (Japan).
• Population: 142 patients with DLB.
• Intervention: Donepezil (5-10mg/day) vs. placebo for 12 weeks.
• Results:
  • Significant improvement in MMSE and NPI (especially hallucinations, apathy).
  • Improved caregiver burden scores.
• Conclusion: Donepezil effective for cognition and neuropsychiatric symptoms in DLB.

Neuroleptic Sensitivity in DLB (McKeith et al., 1992) [9]

• Design: Case series and review.
• Findings: ~50% of DLB patients develop severe sensitivity reactions to neuroleptics (typical antipsychotics).
  • "Symptoms: Rigidity, sedation, confusion, autonomic instability, falls."
  • "Mortality: 13-30% when typical antipsychotics used."
• Conclusion: Typical antipsychotics (haloperidol) are contraindicated in DLB.

DaTscan in DLB Diagnosis (McKeith et al., 2007) [12]

• Design: Multicentre prospective study.
• Population: Patients with suspected DLB vs. Alzheimer's disease.
• Test: FP-CIT SPECT (DaTscan).
• Results:
  • Sensitivity ~80%, Specificity ~90% for differentiating DLB from non-DLB dementia (mainly Alzheimer's).
  • Reduced striatal DAT uptake in DLB; normal in Alzheimer's.
• Conclusion: DaTscan is a valuable diagnostic biomarker for DLB.

RBD and Synucleinopathy Risk (Schenck et al., 2013; Iranzo et al., 2013) [5,6]

• Design: Longitudinal cohort studies of patients with idiopathic RBD.
• Findings:
  • 80-90% of idiopathic RBD patients develop a defined neurodegenerative disease (Parkinson's, DLB, MSA) within 10-14 years.
  • RBD precedes motor/cognitive symptoms by median 10-15 years.
• Conclusion: RBD is a prodromal marker of alpha-synucleinopathy. Provides window for future disease-modifying interventions.

---

14. Future Directions and Research

---

15. Quality Markers and Audit Standards

---

16. Historical Context

---

17. Glossary of Terms

---

18. References

1. Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44(4):673-683. doi:10.1017/S0033291713000494

2. Hogan DB, Fiest KM, Roberts JI, et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci. 2016;43(Suppl 1):S83-S95. doi:10.1017/cjn.2016.2

3. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-840. doi:10.1038/42166

4. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058

5. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder: a 16-year update on a previously reported series. Sleep Med. 2013;14(8):744-748. doi:10.1016/j.sleep.2012.10.009

6. Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12(5):443-453. doi:10.1016/S1474-4422(13)70056-5

7. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport. 1994;5(7):747-749. doi:10.1097/00001756-199403000-00002

8. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673-678. doi:10.1136/bmj.305.6855.673

9. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528-536. doi:10.1002/gps.389

10. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-1707. doi:10.1002/mds.21507

11. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14(1):38-48. doi:10.1038/nrn3406

12. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305-313. doi:10.1016/S1474-4422(07)70057-1

13. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031-2036. doi:10.1016/S0140-6736(00)03399-7

14. Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41-52. doi:10.1002/ana.23557

15. Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67(11):1935-1941. doi:10.1212/01.wnl.0000247041.63081.98

16. Savica R, Grossardt BR, Bower JH, et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70(11):1396-1402. doi:10.1001/jamaneurol.2013.3579

17. Whitwell JL, Weigand SD, Shiung MM, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain. 2007;130(Pt 3):708-719. doi:10.1093/brain/awl388

18. Howlett DR, Whitfield D, Johnson M, et al. Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol. 2015;25(4):401-408. doi:10.1111/bpa.12182

19. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science. 2003;302(5646):841. doi:10.1126/science.1090278

20. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211. doi:10.1016/s0197-4580(02)00065-9

21. Vermeiren Y, De Deyn PP. Targeting the norepinephrinergic system in Parkinson's disease and related disorders: the locus coeruleus story. Neurochem Int. 2017;102:22-32. doi:10.1016/j.neuint.2016.11.009

22. Bonanni L, Thomas A, Tiraboschi P, et al. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690-705. doi:10.1093/brain/awm322

23. Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav Brain Sci. 2005;28(6):737-757. doi:10.1017/S0140525X05000130

24. Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: A United States prospective cohort. Ann Neurol. 2017;81(2):287-297. doi:10.1002/ana.24877

25. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361(17):1651-1661. doi:10.1056/NEJMoa0901281

26. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62(2):181-187. doi:10.1212/wnl.62.2.181

27. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10-S16. doi:10.1212/wnl.48.5_suppl_6.10s

28. Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain. 2009;132(Pt 1):195-203. doi:10.1093/brain/awn298

29. Graff-Radford J, Murray ME, Lowe VJ, et al. Dementia with Lewy bodies: basis of cingulate island sign. Neurology. 2014;83(9):801-809. doi:10.1212/WNL.0000000000000734

30. Stylianou M, Murphy N, Peraza LR, et al. Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis. Clin Neurophysiol. 2018;129(6):1209-1220. doi:10.1016/j.clinph.2018.03.013

31. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10(3):230-240. doi:10.1016/S1474-4422(11)70014-X

32. Kurlan R, Cummings J, Raman R, Thal L; Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356-1363. doi:10.1212/01.wnl.0000260060.60870.89

33. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340(10):757-763. doi:10.1056/NEJM199903113401003

34. Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85-95. PMID: 20191945

35. Vatter S, Stanmore E, Clare L, et al. Care burden and mental ill health in spouses of people with dementia: the role of coping strategies. Clin Interv Aging. 2020;15:1519-1530. doi:10.2147/CIA.Snimi263009

36. Allan LM, Ballard CG, Rowan EN, Kenny RA. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS One. 2009;4(5):e5521. doi:10.1371/journal.pone.0005521

37. Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):435-463. doi:10.1212/CON.0000000000000309

38. Stoessl AJ, Halliday GM, Gomperts SN. Alpha-synuclein imaging in neurodegenerative diseases. Mov Disord. 2021;36(12):2747-2762. doi:10.1002/mds.28790

39. McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743-755. doi:10.1212/WNL.0000000000009323

40. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601. doi:10.1002/mds.26424

41. Lewy FH. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky M, ed. Handbuch der Neurologie. Vol 3. Berlin: Springer; 1912:920-933.

42. Kosaka K. Lewy bodies in cerebral cortex: report of three cases. Acta Neuropathol. 1978;42(2):127-134. doi:10.1007/BF00690978

43. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-1124. doi:10.1212/wnl.47.5.1113

44. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-1872. doi:10.1212/01.wnl.0000187889.17253.b1

---

Last Reviewed: 2026-01-08 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. It does not replace individualized clinical assessment or professional medical advice. If you or a loved one have concerns about memory, movement, or behaviour, please consult a qualified healthcare professional.